 Liron Caplan
Concepts (359)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spondylitis, Ankylosing | 12 | 2024 | 43 | 5.510 |
Why?
| | Arthritis, Rheumatoid | 52 | 2025 | 1177 | 4.720 |
Why?
| | Rheumatology | 15 | 2023 | 133 | 4.050 |
Why?
| | Spondylarthritis | 10 | 2024 | 50 | 3.840 |
Why?
| | Antirheumatic Agents | 27 | 2019 | 308 | 3.380 |
Why?
| | Osteoporosis | 10 | 2023 | 237 | 1.850 |
Why?
| | Glucocorticoids | 11 | 2025 | 531 | 1.680 |
Why?
| | Severity of Illness Index | 26 | 2023 | 2945 | 1.460 |
Why?
| | Health Literacy | 5 | 2019 | 184 | 1.430 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 5 | 2023 | 344 | 1.400 |
Why?
| | Gastrointestinal Diseases | 3 | 2018 | 221 | 1.370 |
Why?
| | Methotrexate | 11 | 2018 | 232 | 1.080 |
Why?
| | Arthritis | 2 | 2019 | 96 | 1.040 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 3 | 2015 | 261 | 1.010 |
Why?
| | Registries | 21 | 2025 | 2410 | 0.920 |
Why?
| | Decision Support Systems, Management | 2 | 2015 | 7 | 0.870 |
Why?
| | Community Health Workers | 1 | 2025 | 88 | 0.840 |
Why?
| | Methylenetetrahydrofolate Reductase (NADPH2) | 2 | 2014 | 35 | 0.790 |
Why?
| | Sacroiliitis | 1 | 2022 | 7 | 0.760 |
Why?
| | Fractures, Bone | 3 | 2023 | 426 | 0.690 |
Why?
| | Cardiovascular Diseases | 9 | 2023 | 2185 | 0.690 |
Why?
| | Bone Density Conservation Agents | 4 | 2014 | 81 | 0.680 |
Why?
| | Veterans | 14 | 2025 | 1626 | 0.680 |
Why?
| | Humans | 102 | 2025 | 145491 | 0.660 |
Why?
| | Outpatient Clinics, Hospital | 2 | 2011 | 80 | 0.640 |
Why?
| | Arthritis, Psoriatic | 2 | 2023 | 15 | 0.630 |
Why?
| | Health Knowledge, Attitudes, Practice | 4 | 2015 | 1417 | 0.630 |
Why?
| | Conflict of Interest | 1 | 2020 | 54 | 0.610 |
Why?
| | Patient Readmission | 1 | 2025 | 769 | 0.610 |
Why?
| | Body Mass Index | 10 | 2018 | 2425 | 0.600 |
Why?
| | Transportation | 1 | 2019 | 56 | 0.590 |
Why?
| | Drug Packaging | 1 | 2019 | 41 | 0.590 |
Why?
| | Inflammatory Bowel Diseases | 3 | 2018 | 366 | 0.570 |
Why?
| | Rheumatic Diseases | 2 | 2018 | 98 | 0.570 |
Why?
| | Gastrointestinal Tract | 2 | 2018 | 208 | 0.560 |
Why?
| | Visual Analog Scale | 2 | 2019 | 34 | 0.550 |
Why?
| | Prednisone | 6 | 2025 | 221 | 0.540 |
Why?
| | Antibodies, Antineutrophil Cytoplasmic | 1 | 2018 | 33 | 0.530 |
Why?
| | Pharmaceutical Preparations | 1 | 2019 | 170 | 0.530 |
Why?
| | United States | 34 | 2025 | 16115 | 0.520 |
Why?
| | Vasculitis | 1 | 2018 | 69 | 0.520 |
Why?
| | Joints | 3 | 2013 | 107 | 0.520 |
Why?
| | Aged | 45 | 2025 | 26125 | 0.510 |
Why?
| | Disability Evaluation | 2 | 2018 | 311 | 0.510 |
Why?
| | Medication Therapy Management | 1 | 2018 | 72 | 0.510 |
Why?
| | Diphosphonates | 3 | 2014 | 68 | 0.490 |
Why?
| | Tumor Necrosis Factor-alpha | 8 | 2022 | 1212 | 0.490 |
Why?
| | Middle Aged | 49 | 2025 | 36176 | 0.490 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2018 | 138 | 0.480 |
Why?
| | Health Care Costs | 1 | 2019 | 427 | 0.440 |
Why?
| | Cross-Sectional Studies | 16 | 2019 | 5891 | 0.440 |
Why?
| | Male | 58 | 2025 | 72817 | 0.430 |
Why?
| | Patient Satisfaction | 2 | 2019 | 710 | 0.430 |
Why?
| | Liver Diseases | 1 | 2018 | 304 | 0.430 |
Why?
| | Patient Education as Topic | 4 | 2015 | 775 | 0.430 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2025 | 1755 | 0.430 |
Why?
| | Practice Patterns, Physicians' | 3 | 2015 | 1369 | 0.420 |
Why?
| | gamma-Glutamyl Hydrolase | 1 | 2014 | 3 | 0.410 |
Why?
| | Peptide Synthases | 1 | 2014 | 4 | 0.410 |
Why?
| | Surveys and Questionnaires | 7 | 2016 | 6070 | 0.410 |
Why?
| | Veterans Health | 5 | 2017 | 189 | 0.410 |
Why?
| | Attitude of Health Personnel | 2 | 2013 | 1188 | 0.410 |
Why?
| | Weight Loss | 5 | 2018 | 839 | 0.410 |
Why?
| | Diabetes Mellitus, Type 2 | 4 | 2022 | 2582 | 0.410 |
Why?
| | Proteins | 1 | 2019 | 1020 | 0.390 |
Why?
| | Spondylarthropathies | 3 | 2019 | 5 | 0.390 |
Why?
| | Health Status | 3 | 2018 | 836 | 0.380 |
Why?
| | Protein Kinase Inhibitors | 1 | 2019 | 980 | 0.380 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 2015 | 182 | 0.380 |
Why?
| | Risk Factors | 24 | 2023 | 10874 | 0.380 |
Why?
| | Societies, Medical | 5 | 2019 | 898 | 0.370 |
Why?
| | Biomedical Research | 1 | 2019 | 718 | 0.370 |
Why?
| | Symptom Assessment | 1 | 2013 | 136 | 0.370 |
Why?
| | Female | 51 | 2025 | 78763 | 0.370 |
Why?
| | Consumer Behavior | 1 | 2013 | 70 | 0.370 |
Why?
| | Lipids | 2 | 2014 | 709 | 0.370 |
Why?
| | Activities of Daily Living | 1 | 2016 | 441 | 0.360 |
Why?
| | Folic Acid | 1 | 2014 | 198 | 0.360 |
Why?
| | Physical Therapy Modalities | 1 | 2015 | 335 | 0.360 |
Why?
| | Pharmacists | 1 | 2015 | 259 | 0.350 |
Why?
| | Hospitals, Public | 1 | 2011 | 30 | 0.340 |
Why?
| | Patient Reported Outcome Measures | 1 | 2016 | 497 | 0.340 |
Why?
| | Obesity | 5 | 2018 | 3076 | 0.340 |
Why?
| | Health Personnel | 3 | 2014 | 750 | 0.340 |
Why?
| | Pain | 2 | 2022 | 787 | 0.330 |
Why?
| | Electronic Health Records | 3 | 2015 | 1187 | 0.330 |
Why?
| | Anti-Inflammatory Agents | 4 | 2018 | 478 | 0.310 |
Why?
| | Autoantibodies | 5 | 2019 | 1512 | 0.300 |
Why?
| | Telemedicine | 1 | 2019 | 960 | 0.290 |
Why?
| | Efficiency, Organizational | 1 | 2010 | 141 | 0.290 |
Why?
| | Cerebrovascular Disorders | 3 | 1997 | 106 | 0.290 |
Why?
| | Linear Models | 5 | 2019 | 848 | 0.290 |
Why?
| | Adalimumab | 4 | 2020 | 55 | 0.290 |
Why?
| | Workflow | 1 | 2010 | 184 | 0.280 |
Why?
| | Musculoskeletal Diseases | 1 | 2010 | 90 | 0.280 |
Why?
| | Physician-Patient Relations | 2 | 2011 | 590 | 0.280 |
Why?
| | Publications | 1 | 2008 | 48 | 0.270 |
Why?
| | Practice Guidelines as Topic | 5 | 2018 | 1585 | 0.270 |
Why?
| | Ethics, Medical | 1 | 2008 | 90 | 0.260 |
Why?
| | CARD Signaling Adaptor Proteins | 2 | 2024 | 22 | 0.260 |
Why?
| | Patient Compliance | 1 | 2012 | 587 | 0.260 |
Why?
| | Etanercept | 3 | 2016 | 60 | 0.250 |
Why?
| | United States Department of Veterans Affairs | 8 | 2016 | 775 | 0.250 |
Why?
| | Observational Studies as Topic | 2 | 2025 | 133 | 0.250 |
Why?
| | Radiography | 3 | 2019 | 852 | 0.240 |
Why?
| | Infliximab | 3 | 2016 | 111 | 0.240 |
Why?
| | Diabetes Mellitus | 1 | 2015 | 1076 | 0.240 |
Why?
| | Aged, 80 and over | 11 | 2019 | 8326 | 0.230 |
Why?
| | Time Factors | 12 | 2018 | 7171 | 0.230 |
Why?
| | Drug Utilization | 3 | 2018 | 167 | 0.230 |
Why?
| | Adult | 20 | 2023 | 40707 | 0.230 |
Why?
| | Professional Practice | 1 | 2005 | 57 | 0.220 |
Why?
| | Ambulatory Care | 1 | 2010 | 608 | 0.220 |
Why?
| | Treatment Outcome | 13 | 2019 | 11831 | 0.220 |
Why?
| | Peptides, Cyclic | 4 | 2016 | 275 | 0.210 |
Why?
| | Longitudinal Studies | 9 | 2019 | 2950 | 0.210 |
Why?
| | HLA-B27 Antigen | 2 | 2024 | 16 | 0.200 |
Why?
| | Adrenal Cortex Hormones | 1 | 2007 | 482 | 0.200 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2019 | 2146 | 0.200 |
Why?
| | Reproducibility of Results | 5 | 2016 | 3424 | 0.200 |
Why?
| | Rheumatoid Factor | 3 | 2016 | 178 | 0.200 |
Why?
| | Quality of Life | 1 | 2016 | 3195 | 0.200 |
Why?
| | Evidence-Based Medicine | 2 | 2018 | 738 | 0.190 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2014 | 2030 | 0.190 |
Why?
| | Cohort Studies | 11 | 2015 | 5992 | 0.190 |
Why?
| | Bone Density | 4 | 2023 | 484 | 0.190 |
Why?
| | Predictive Value of Tests | 5 | 2018 | 2129 | 0.190 |
Why?
| | Magnetic Resonance Imaging | 4 | 2025 | 3897 | 0.180 |
Why?
| | Myocardial Infarction | 3 | 2018 | 1216 | 0.180 |
Why?
| | Retrospective Studies | 11 | 2022 | 17269 | 0.170 |
Why?
| | Inflammation | 4 | 2018 | 2883 | 0.170 |
Why?
| | Biomarkers | 5 | 2022 | 4283 | 0.170 |
Why?
| | Self Report | 1 | 2025 | 871 | 0.160 |
Why?
| | Lymphocytes | 1 | 2022 | 379 | 0.160 |
Why?
| | Multivariate Analysis | 8 | 2018 | 1544 | 0.160 |
Why?
| | Prognosis | 6 | 2016 | 4323 | 0.160 |
Why?
| | C-Reactive Protein | 3 | 2017 | 422 | 0.160 |
Why?
| | Neutrophils | 2 | 2024 | 1124 | 0.160 |
Why?
| | Proportional Hazards Models | 6 | 2016 | 1332 | 0.160 |
Why?
| | Genetic Predisposition to Disease | 5 | 2024 | 2355 | 0.160 |
Why?
| | Granuloma, Foreign-Body | 1 | 2020 | 8 | 0.160 |
Why?
| | Regression Analysis | 3 | 2011 | 1001 | 0.150 |
Why?
| | Tattooing | 1 | 2020 | 12 | 0.150 |
Why?
| | Risk Assessment | 7 | 2018 | 3759 | 0.150 |
Why?
| | Genotype | 3 | 2014 | 1853 | 0.150 |
Why?
| | Comorbidity | 6 | 2018 | 1659 | 0.150 |
Why?
| | Malondialdehyde | 1 | 2019 | 30 | 0.150 |
Why?
| | Acetaldehyde | 1 | 2019 | 17 | 0.150 |
Why?
| | Macular Edema | 1 | 2020 | 49 | 0.150 |
Why?
| | Blood Platelets | 1 | 2022 | 380 | 0.150 |
Why?
| | Drug Stability | 1 | 2019 | 169 | 0.150 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2019 | 28 | 0.140 |
Why?
| | Protein Stability | 1 | 2019 | 178 | 0.140 |
Why?
| | Drug Compounding | 1 | 2019 | 107 | 0.140 |
Why?
| | Deprescriptions | 1 | 2019 | 37 | 0.140 |
Why?
| | Drug Monitoring | 2 | 2012 | 400 | 0.140 |
Why?
| | Metformin | 1 | 2022 | 324 | 0.140 |
Why?
| | Intraepithelial Lymphocytes | 1 | 2018 | 16 | 0.140 |
Why?
| | Uveitis | 1 | 2020 | 149 | 0.140 |
Why?
| | Vertebrobasilar Insufficiency | 1 | 1998 | 10 | 0.140 |
Why?
| | Pyrroles | 1 | 2019 | 213 | 0.140 |
Why?
| | Blood Glucose | 4 | 2022 | 2330 | 0.140 |
Why?
| | Hydroxychloroquine | 2 | 2018 | 65 | 0.140 |
Why?
| | Clinical Trials as Topic | 2 | 2022 | 1058 | 0.130 |
Why?
| | Cerebral Infarction | 1 | 1998 | 47 | 0.130 |
Why?
| | Mesencephalon | 1 | 1998 | 65 | 0.130 |
Why?
| | Piperidines | 1 | 2019 | 221 | 0.130 |
Why?
| | Stress, Mechanical | 1 | 2019 | 495 | 0.130 |
Why?
| | Obesity, Abdominal | 1 | 2017 | 46 | 0.130 |
Why?
| | Inflammation Mediators | 2 | 2017 | 505 | 0.130 |
Why?
| | Remission Induction | 3 | 2012 | 309 | 0.120 |
Why?
| | Absorptiometry, Photon | 3 | 2017 | 276 | 0.120 |
Why?
| | Drug Administration Schedule | 2 | 2010 | 782 | 0.120 |
Why?
| | Thrombolytic Therapy | 1 | 1997 | 166 | 0.120 |
Why?
| | Temperature | 1 | 2019 | 681 | 0.120 |
Why?
| | Sodium Chloride | 1 | 2016 | 143 | 0.120 |
Why?
| | Biological Products | 1 | 2019 | 258 | 0.120 |
Why?
| | Research Design | 1 | 2022 | 1134 | 0.120 |
Why?
| | Pyrimidines | 1 | 2019 | 520 | 0.110 |
Why?
| | Tissue Plasminogen Activator | 1 | 1997 | 249 | 0.110 |
Why?
| | Administration, Oral | 2 | 2025 | 863 | 0.110 |
Why?
| | Genes, rel | 1 | 2014 | 4 | 0.110 |
Why?
| | Patient Selection | 3 | 2022 | 742 | 0.110 |
Why?
| | DNA Methylation | 1 | 2019 | 667 | 0.100 |
Why?
| | Lipoproteins, LDL | 1 | 2014 | 119 | 0.100 |
Why?
| | Lipoproteins, HDL | 1 | 2014 | 99 | 0.100 |
Why?
| | Hand | 1 | 2015 | 161 | 0.100 |
Why?
| | Disease Management | 1 | 2018 | 654 | 0.100 |
Why?
| | Vascular Calcification | 1 | 2015 | 114 | 0.100 |
Why?
| | Diagnosis, Differential | 1 | 2018 | 1507 | 0.100 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2019 | 994 | 0.100 |
Why?
| | Spinal Fractures | 1 | 2014 | 76 | 0.100 |
Why?
| | Incidence | 7 | 2018 | 2915 | 0.100 |
Why?
| | Femoral Fractures | 1 | 2014 | 84 | 0.090 |
Why?
| | Adiposity | 1 | 2017 | 529 | 0.090 |
Why?
| | Lung Diseases, Interstitial | 1 | 2019 | 660 | 0.090 |
Why?
| | Algorithms | 2 | 2025 | 1855 | 0.090 |
Why?
| | Immunosuppressive Agents | 3 | 2009 | 842 | 0.090 |
Why?
| | Health Services Research | 1 | 2015 | 392 | 0.090 |
Why?
| | Dyslipidemias | 1 | 2014 | 184 | 0.090 |
Why?
| | Immunoglobulin G | 1 | 2016 | 890 | 0.090 |
Why?
| | North America | 1 | 2013 | 312 | 0.090 |
Why?
| | Chronic Disease | 2 | 2018 | 1816 | 0.090 |
Why?
| | Insurance, Pharmaceutical Services | 1 | 2011 | 24 | 0.090 |
Why?
| | Triglycerides | 1 | 2014 | 518 | 0.090 |
Why?
| | Lung Diseases | 1 | 2018 | 783 | 0.090 |
Why?
| | Polymorphism, Genetic | 2 | 2011 | 616 | 0.090 |
Why?
| | Autoimmunity | 1 | 2018 | 936 | 0.090 |
Why?
| | Coronary Artery Disease | 1 | 2018 | 760 | 0.080 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2011 | 87 | 0.080 |
Why?
| | Antibodies, Monoclonal | 2 | 2016 | 1511 | 0.080 |
Why?
| | Glutathione Transferase | 1 | 2010 | 96 | 0.080 |
Why?
| | Memory Disorders | 1 | 2012 | 198 | 0.080 |
Why?
| | Nanoparticles | 1 | 2016 | 519 | 0.080 |
Why?
| | Gastrointestinal Microbiome | 1 | 2018 | 774 | 0.080 |
Why?
| | Health Care Surveys | 1 | 2012 | 538 | 0.080 |
Why?
| | Workload | 1 | 2012 | 168 | 0.080 |
Why?
| | HLA-DR Antigens | 1 | 2010 | 220 | 0.080 |
Why?
| | Young Adult | 3 | 2019 | 14192 | 0.080 |
Why?
| | Sex Factors | 4 | 2017 | 2110 | 0.070 |
Why?
| | Hypertension | 1 | 2018 | 1273 | 0.070 |
Why?
| | Follow-Up Studies | 4 | 2015 | 5426 | 0.070 |
Why?
| | Health Surveys | 2 | 2012 | 518 | 0.070 |
Why?
| | Hip Fractures | 1 | 2010 | 87 | 0.070 |
Why?
| | Immunocompromised Host | 2 | 2011 | 202 | 0.070 |
Why?
| | Cytokines | 1 | 2016 | 2054 | 0.070 |
Why?
| | Disease Progression | 4 | 2019 | 2862 | 0.070 |
Why?
| | Epitopes | 1 | 2010 | 480 | 0.070 |
Why?
| | Databases, Bibliographic | 1 | 2008 | 30 | 0.070 |
Why?
| | Vitamin D Deficiency | 1 | 2010 | 190 | 0.070 |
Why?
| | Beneficence | 1 | 2008 | 20 | 0.070 |
Why?
| | Self Care | 1 | 2011 | 389 | 0.070 |
Why?
| | Pilot Projects | 1 | 2014 | 1896 | 0.070 |
Why?
| | Hospitalization | 2 | 2011 | 2458 | 0.070 |
Why?
| | Awards and Prizes | 1 | 1989 | 72 | 0.070 |
Why?
| | Sensitivity and Specificity | 1 | 2013 | 2002 | 0.070 |
Why?
| | Interviews as Topic | 1 | 2012 | 909 | 0.070 |
Why?
| | Drug Prescriptions | 1 | 2010 | 287 | 0.070 |
Why?
| | Prospective Studies | 4 | 2013 | 8039 | 0.070 |
Why?
| | Social Justice | 1 | 2008 | 82 | 0.070 |
Why?
| | Neoplasms | 3 | 2017 | 2897 | 0.060 |
Why?
| | Urban Population | 1 | 2010 | 494 | 0.060 |
Why?
| | Research Personnel | 1 | 1989 | 187 | 0.060 |
Why?
| | Self Administration | 1 | 2007 | 124 | 0.060 |
Why?
| | Infusions, Intravenous | 2 | 2016 | 427 | 0.060 |
Why?
| | Depressive Disorder | 1 | 2009 | 387 | 0.060 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2011 | 644 | 0.060 |
Why?
| | Quality of Health Care | 1 | 2011 | 693 | 0.060 |
Why?
| | Herpes Zoster | 1 | 2009 | 318 | 0.060 |
Why?
| | Age Factors | 4 | 2015 | 3340 | 0.060 |
Why?
| | Respiratory Tract Diseases | 2 | 2017 | 176 | 0.060 |
Why?
| | Military Personnel | 1 | 2013 | 737 | 0.050 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2013 | 891 | 0.050 |
Why?
| | Cause of Death | 2 | 2017 | 469 | 0.050 |
Why?
| | Qualitative Research | 1 | 2012 | 1677 | 0.050 |
Why?
| | Skin Neoplasms | 1 | 2011 | 850 | 0.050 |
Why?
| | Spine | 1 | 2025 | 182 | 0.050 |
Why?
| | Coculture Techniques | 1 | 2024 | 246 | 0.050 |
Why?
| | Interleukin-17 | 1 | 2024 | 120 | 0.050 |
Why?
| | Immunity, Innate | 2 | 2024 | 846 | 0.050 |
Why?
| | Survival Analysis | 2 | 2018 | 1374 | 0.050 |
Why?
| | Databases, Factual | 3 | 2014 | 1500 | 0.050 |
Why?
| | Th17 Cells | 1 | 2024 | 100 | 0.050 |
Why?
| | Autoantigens | 2 | 2019 | 426 | 0.050 |
Why?
| | Antibody Formation | 2 | 2019 | 291 | 0.050 |
Why?
| | Isoxazoles | 2 | 2016 | 55 | 0.040 |
Why?
| | Adolescent | 3 | 2019 | 22485 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2004 | 456 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2019 | 3619 | 0.040 |
Why?
| | Carrier Proteins | 1 | 2004 | 733 | 0.040 |
Why?
| | Pneumonia | 1 | 2006 | 632 | 0.040 |
Why?
| | Prevalence | 1 | 2007 | 2855 | 0.040 |
Why?
| | Foreign-Body Reaction | 1 | 2020 | 36 | 0.040 |
Why?
| | Phospholipase D | 1 | 2019 | 7 | 0.040 |
Why?
| | Steroids | 1 | 2020 | 160 | 0.040 |
Why?
| | Sulfasalazine | 1 | 2018 | 22 | 0.030 |
Why?
| | Intracranial Embolism and Thrombosis | 1 | 1998 | 7 | 0.030 |
Why?
| | New England | 1 | 1998 | 37 | 0.030 |
Why?
| | Coronary Thrombosis | 1 | 1998 | 27 | 0.030 |
Why?
| | Microtubule-Associated Proteins | 1 | 2019 | 197 | 0.030 |
Why?
| | Blood Sedimentation | 1 | 2017 | 37 | 0.030 |
Why?
| | Infusions, Intra-Arterial | 1 | 1997 | 61 | 0.030 |
Why?
| | Vulnerable Populations | 1 | 2019 | 175 | 0.030 |
Why?
| | Child | 3 | 2023 | 22680 | 0.030 |
Why?
| | Molecular Chaperones | 1 | 2019 | 182 | 0.030 |
Why?
| | RNA, Long Noncoding | 1 | 2019 | 172 | 0.030 |
Why?
| | Rheumatic Nodule | 1 | 2016 | 3 | 0.030 |
Why?
| | Mitochondrial Proteins | 1 | 2019 | 262 | 0.030 |
Why?
| | Visual Acuity | 1 | 2020 | 491 | 0.030 |
Why?
| | Osteoarthritis | 1 | 2019 | 200 | 0.030 |
Why?
| | Consensus | 1 | 2018 | 483 | 0.030 |
Why?
| | Adsorption | 1 | 2016 | 153 | 0.030 |
Why?
| | Biopsy | 1 | 2020 | 1081 | 0.030 |
Why?
| | Machine Learning | 1 | 2022 | 590 | 0.030 |
Why?
| | Thinness | 1 | 2016 | 99 | 0.030 |
Why?
| | Nutrition Surveys | 1 | 2017 | 280 | 0.030 |
Why?
| | Protein Aggregates | 1 | 2016 | 84 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2016 | 171 | 0.030 |
Why?
| | Drug Substitution | 1 | 2016 | 63 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2004 | 1996 | 0.030 |
Why?
| | Chemokines | 1 | 2016 | 218 | 0.030 |
Why?
| | Cerebrovascular Circulation | 1 | 1998 | 289 | 0.030 |
Why?
| | Mortality | 1 | 2018 | 379 | 0.030 |
Why?
| | Particle Size | 1 | 2016 | 402 | 0.030 |
Why?
| | Lymphoma | 1 | 2016 | 234 | 0.030 |
Why?
| | Apolipoproteins E | 1 | 2015 | 94 | 0.030 |
Why?
| | Interleukin-4 | 1 | 2015 | 208 | 0.030 |
Why?
| | Epigenesis, Genetic | 1 | 2019 | 672 | 0.030 |
Why?
| | Leukemia | 1 | 2016 | 246 | 0.030 |
Why?
| | Antigen-Antibody Complex | 1 | 2014 | 70 | 0.030 |
Why?
| | Cardiac Catheterization | 1 | 2018 | 570 | 0.030 |
Why?
| | Hospitals, Veterans | 1 | 2015 | 259 | 0.030 |
Why?
| | United States Food and Drug Administration | 1 | 2014 | 207 | 0.020 |
Why?
| | Causality | 1 | 2014 | 127 | 0.020 |
Why?
| | Life Style | 1 | 2016 | 483 | 0.020 |
Why?
| | Mutation | 1 | 2024 | 4093 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2019 | 1378 | 0.020 |
Why?
| | Hypoglycemic Agents | 1 | 2022 | 1392 | 0.020 |
Why?
| | Body Weight | 1 | 2016 | 970 | 0.020 |
Why?
| | Blood Pressure | 1 | 2018 | 1782 | 0.020 |
Why?
| | Data Mining | 1 | 2011 | 115 | 0.020 |
Why?
| | HLA-DRB1 Chains | 1 | 2010 | 110 | 0.020 |
Why?
| | Survival Rate | 1 | 2015 | 2093 | 0.020 |
Why?
| | Logistic Models | 1 | 2015 | 2130 | 0.020 |
Why?
| | Mice | 2 | 2024 | 18338 | 0.020 |
Why?
| | Propensity Score | 1 | 2011 | 376 | 0.020 |
Why?
| | Smoking | 1 | 2016 | 1468 | 0.020 |
Why?
| | Prostatic Neoplasms | 1 | 2016 | 978 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 839 | 0.020 |
Why?
| | Risk | 1 | 2011 | 917 | 0.020 |
Why?
| | Medication Adherence | 1 | 2012 | 543 | 0.020 |
Why?
| | Pancreatic Neoplasms | 1 | 2016 | 928 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2010 | 1049 | 0.020 |
Why?
| | Congresses as Topic | 1 | 1989 | 223 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 1997 | 2772 | 0.020 |
Why?
| | American Heart Association | 1 | 1989 | 360 | 0.020 |
Why?
| | Periodicals as Topic | 1 | 1989 | 210 | 0.010 |
Why?
| | Lung | 1 | 2019 | 4103 | 0.010 |
Why?
| | Population Surveillance | 1 | 2009 | 485 | 0.010 |
Why?
| | Signaling Lymphocytic Activation Molecule Associated Protein | 1 | 2004 | 1 | 0.010 |
Why?
| | Signaling Lymphocytic Activation Molecule Family Member 1 | 1 | 2004 | 2 | 0.010 |
Why?
| | Lupus Vulgaris | 1 | 2004 | 5 | 0.010 |
Why?
| | Socioeconomic Factors | 1 | 2009 | 1327 | 0.010 |
Why?
| | Animals | 2 | 2024 | 38141 | 0.010 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 1 | 2004 | 70 | 0.010 |
Why?
| | Immunoglobulins | 1 | 2004 | 162 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 2016 | 2664 | 0.010 |
Why?
| | Forecasting | 1 | 2004 | 391 | 0.010 |
Why?
| | Glycoproteins | 1 | 2004 | 353 | 0.010 |
Why?
| | Receptors, Cell Surface | 1 | 2004 | 372 | 0.010 |
Why?
| | Drug Therapy, Combination | 1 | 2004 | 1046 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 2004 | 1261 | 0.010 |
Why?
| | Antigens, CD | 1 | 2004 | 557 | 0.010 |
Why?
| | Cell Membrane | 1 | 2004 | 707 | 0.010 |
Why?
| | Autoimmune Diseases | 1 | 2004 | 469 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2004 | 3125 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2004 | 4559 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2004 | 5989 | 0.010 |
Why?
| | Signal Transduction | 1 | 2004 | 5202 | 0.010 |
Why?
|
|
Caplan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|